Lu-Yi Lu

CEO
Novascope Diagnostics Inc.

​​​
​Dr. Lu-Yi Lu, Ph.D., is the Co-founder and CEO of Novascope Diagnostics Inc., a biomedical startup advancing high-sensitivity diagnostic platforms for early disease detection and precision health. With a multidisciplinary background spanning biotechnology, chemistry, and electronics, Dr. Lu leads innovations in biosensors and diagnostic applications for aging-related and neurodegenerative diseases.
Before founding Novascope in 2022, Dr. Lu served as a senior strategic analyst at the Formosa Plastics Group, where he evaluated over 100 biotech investment opportunities and led post-investment management for late-stage pharmaceutical assets. He also directed an intersectoral aging-health initiative that integrated clinical, academic, and industrial resources, supporting more than 20 experts under an annual grant exceeding 20 million NTD.
Dr. Lu conducted postdoctoral research in peptide drug discovery and pharmacokinetics at the University of Tokyo, where he contributed to the development of a preclinical candidate. He also held academic appointments as a research fellow in Japan and as an academic visitor at Birkbeck College, University of London. His academic training includes a Ph.D. in biotechnology, an M.S. in biological sciences, and a B.S. in applied chemistry from National Chiao Tung University in Taiwan.
His scientific interests lie in biosensing technologies, bioelectronics, and the interface of diagnostics with precision medicine. Dr. Lu is a certified industrial analyst and recipient of numerous international fellowships and research awards from institutions such as the Japan Society, the Ministry of Science and Technology (Taiwan), and the American Society for Biochemistry and Molecular Biology.

Development of Blood-based Diagnostics with BioChips Reaction (BCR) Platform

.